T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Forum Energy Technologies
FET
$927M
| $103M | 0.02% |
141,435
+5,138
| +4% | +$3.35M |
|
627
Novartis
NVS
$288B
| $102M | 0.02% |
1,261,558
+1,243,247
| +6,790% | +$97.8M |
|
|
GRUB
628
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
| $102M | 0.02% |
+1,478,981
| New | +$99.6M |
|
|
JBTM
629
JBT Marel
JBTM
$6.1B
| $101M | 0.02% |
3,270,365
+72,660
| +2% | +$2.16M |
|
630
Graham Holdings Company
GHC
$4.97B
| $101M | 0.02% |
233,516
-19,247
| -8% | -$8.01M |
|
631
Jacobs Solutions
J
$16.8B
| $100M | 0.02% |
2,269,402
-139,195
| -6% | -$6.63M |
|
|
CJES
632
DELISTED
C&J ENERGY SVCS LTD
CJES
| $99.9M | 0.02% |
2,958,100
-427,520
| -13% | -$13.1M |
|
633
Eli Lilly
LLY
$1.08T
| $99.9M | 0.02% |
1,606,407
+16,245
| +1% | +$969K |
|
|
SNDK
634
DELISTED
SANDISK CORP
SNDK
| $99M | 0.02% |
948,429
-5,581
| -0.6% | -$507K |
|
635
HUB Group
HUBG
$2.55B
| $98.9M | 0.02% |
3,925,320
-791,708
| -17% | -$18M |
|
636
TJX Companies
TJX
$170B
| $98.6M | 0.02% |
3,710,016
-24,240
| -0.6% | -$692K |
|
637
M&T Bank
MTB
$36.6B
| $98.4M | 0.02% |
793,591
-583,936
| -42% | -$71.1M |
|
|
PF
638
DELISTED
Pinnacle Foods, Inc.
PF
| $98.1M | 0.02% |
2,981,480
-18,850
| -0.6% | -$594K |
|
|
OPEN
639
DELISTED
OPENTABLE,INC COMMON STOCK
OPEN
| $98M | 0.02% |
946,433
-1,196,477
| -56% | -$91.3M |
|
|
TCO
640
DELISTED
Taubman Centers Inc.
TCO
| $97.4M | 0.02% |
1,285,308
-24,563
| -2% | -$1.81M |
|
641
Omnicom Group
OMC
$24.2B
| $97.2M | 0.02% |
1,365,168
-59,233
| -4% | -$4.13M |
|
|
HR
642
DELISTED
Healthcare Realty Trust Incorporated
HR
| $96.9M | 0.02% |
3,812,685
-112,236
| -3% | -$2.8M |
|
|
SGEN
643
DELISTED
Seagen Inc. Common Stock
SGEN
| $96.9M | 0.02% |
2,532,789
-308,414
| -11% | -$11.7M |
|
|
RWT
644
Redwood Trust
RWT
$599M
| $96.3M | 0.02% |
4,947,904
-29,767
| -0.6% | -$595K |
|
645
CME Group
CME
$96.1B
| $95.9M | 0.02% |
1,352,195
-261,115
| -16% | -$18.4M |
|
646
ON Semiconductor
ON
$31.8B
| $95.5M | 0.02% |
10,453,539
-16,083,700
| -61% | -$146M |
|
647
Scholastic
SCHL
$784M
| $95.4M | 0.02% |
2,798,918
+457,510
| +20% | +$14.9M |
|
648
Ionis Pharmaceuticals
IONS
$9.28B
| $95.3M | 0.02% |
2,766,278
-462,979
| -14% | -$14.6M |
|
|
CAVM
649
DELISTED
Cavium, Inc.
CAVM
| $95.1M | 0.02% |
1,914,870
-542,440
| -22% | -$24.9M |
|
650
Bloomin' Brands
BLMN
$924M
| $94.3M | 0.02% |
4,206,380
-487,295
| -10% | -$10.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.